EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

LGALS3 cfDNA methylation in seminal fluid as a novel prostate cancer biomarker outperforming PSA

Irena Abramovic iD, Ivan Pezelj, Leo Dumbovic, Lucija Skara Abramovic, Tonci Vodopic, Stela Bulimbasic, Goran Stimac, Floriana Bulic-Jakus, Tomislav Kulis, Ana Katusic Bojanac, Davor Tomas, Monika Ulamec und 1 weitere

The Prostate · 2024

DOI: 10.1002/pros.24749 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Prostate, 2024. Verfasst von Irena Abramovic und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Biology, University of Zagreb School of Medicine, Zagreb, Croatia. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Biomarkers, Tumor, DNA Methylation, Prostate-Specific Antigen. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Croatian Science Foundation, Scientific Center of Excellence for Reproductive and Regenerative Medicine, European Regional Development Fund.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The unmet challenge in prostate cancer (PCa) management is to discriminate it from benign prostate hyperplasia (BPH) due to the lack of specific diagnostic biomarkers. Contemporary research on potential PCa biomarkers is directed toward methylated cell‐free DNA (cfDNA) from liquid biopsies since epigenetic mechanisms are strongly involved in PCa development.

Methods

In the present research, cfDNA methylation of the LGALS3 gene in blood and seminal plasma of PCa and BPH patients was assessed using pyrosequencing, as well as LGALS3 DNA methylation in tissue biopsies. Liquid biopsy samples were taken from patients with clinical suspicion of PCa, who were subsequently divided into two groups, that is, 42 with PCa and 55 with BPH, according to the histopathological analysis.

Results

Statistically significant higher cfDNA methylation of LGALS3 in seminal plasma of BPH than in PCa patients was detected by pyrosequencing. ROC curve analysis showed that it could distinguish PCa and BPH patients with 56.4% sensitivity and 70.4% specificity, while PSA did not differ between the two patient groups. In contrast, there was no statistically significant difference in LGALS3 cfDNA methylation in blood plasma between the two patient groups. In prostate tumor tissue, there was a statistically significant DNA hypermethylation of LGALS3 compared to surrounding nontumor tissue and BPH tissue.

Conclusions

The DNA hypermethylation of the LGALS3 gene represents an event specific to PCa development. In conclusion, LGALS3 cfDNA methylation in seminal fluid discriminates early PCa and BPH presenting itself as a powerful novel PCa biomarker highly outperforming PSA.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prostatic NeoplasmsBiomarkers, TumorDNA MethylationProstate-Specific AntigenProstatic HyperplasiaSemenHumansMaleAgedMiddle AgedCell-Free Nucleic AcidsGalectin 3Sensitivity and SpecificityBlood ProteinsGalectins

Stichwörter der Autor:innen

DNA methylationLGALS3biomarkersliquid biopsyprostate cancerseminal plasma

Substanzen

Biomarkers, TumorProstate-Specific AntigenCell-Free Nucleic AcidsLGALS3 protein, humanGalectin 3Blood ProteinsGalectins

Autor:innen und Institutionen

  • Department of Medical Biology, University of Zagreb School of Medicine, Zagreb, Croatia.
  • Scientific Group for Research on Epigenetic Biomarkers, University of Zagreb School of Medicine, Zagreb, Croatia.
  • Scientific Centre of Excellence for Reproductive & Regenerative Medicine, University of Zagreb School of Medicine, Zagreb, Croatia.
  • Department of Urology, University Clinical Hospital Center Sestre Milosrdnice, Zagreb, Croatia.
  • Department of Pathology, Cytology and Forensic Medicine, Varazdin General Hospital, Varazdin, Croatia.
  • Department of Pathology and Cytology, University Hospital Centre Zagreb, Zagreb, Croatia.

ORCID-Profile: Irena Abramovic

Förderung

  • Croatian Science Foundation
  • Scientific Center of Excellence for Reproductive and Regenerative Medicine
  • European Regional Development Fund
  • School of Medicine University of Zagreb

Zitieren

APA

Abramovic, I., Pezelj, I., Dumbovic, L., Skara Abramovic, L., Vodopic, T., Bulimbasic, S., Stimac, G., Bulic-Jakus, F., Kulis, T., Katusic Bojanac, A., Tomas, D., Ulamec, M., & Sincic, N. (2024). LGALS3 cfDNA methylation in seminal fluid as a novel prostate cancer biomarker outperforming PSA. The Prostate. https://doi.org/10.1002/pros.24749

Vancouver

Abramovic I, Pezelj I, Dumbovic L, Skara Abramovic L, Vodopic T, Bulimbasic S, et al. LGALS3 cfDNA methylation in seminal fluid as a novel prostate cancer biomarker outperforming PSA. The Prostate. 2024. doi:10.1002/pros.24749

BibTeX
@article{Abramovic2024,
  author = {Abramovic, Irena and Pezelj, Ivan and Dumbovic, Leo and Skara Abramovic, Lucija and Vodopic, Tonci and Bulimbasic, Stela and Stimac, Goran and Bulic-Jakus, Floriana and Kulis, Tomislav and Katusic Bojanac, Ana and Tomas, Davor and Ulamec, Monika and Sincic, Nino},
  title = {LGALS3 cfDNA methylation in seminal fluid as a novel prostate cancer biomarker outperforming PSA},
  journal = {The Prostate},
  year = {2024},
  doi = {10.1002/pros.24749}
}
Kostenlos starten →